Pricing Log in Create free account

Erasca, Inc. (ERAS) vs PTC Therapeutics, Inc. (PTCT)

Erasca, Inc. and PTC Therapeutics, Inc. are both Biotechnology companies. PTC Therapeutics, Inc. is the larger, with a market value of $5.5B against $4.6B — 1.2× the size. Erasca, Inc. has the higher net margin (0.00% vs −9.17%) and the lower return on invested capital (−203.1% vs 17.7%). Across the 13 metrics below, PTC Therapeutics, Inc. leads on 10 and Erasca, Inc. on 3.

Valuation

Metric ERAS PTCT Biotechnology median
P/E n/m n/m 10.60
P/S n/m 4.74 9.40
P/B 12.34 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 32.25 0.66
EV/Sales n/m 5.35 9.02
Earnings yield (6.62%) (2.00%) (32.88%)
Free cash flow yield (5.65%) (4.74%) (23.13%)

Profitability

Metric ERAS PTCT Biotechnology median
Gross margin 0.00% 93.20% 68.51%
Operating margin 0.00% 12.78% 0.00%
Net margin 0.00% (9.17%) 0.00%
Free cash flow margin 0.00% (22.43%) 0.00%
Return on equity (78.25%) 61.08% (51.96%)
Return on assets (65.25%) (3.62%) (46.06%)
Return on invested capital (203.13%) 17.66% 0.00%

Growth

Metric ERAS PTCT Biotechnology median
Revenue growth (TTM) — (35.05%) 6.76%
EPS growth (last fiscal year) 36.23% 264.48% 29.88%
Revenue growth, 5-year CAGR — 35.37% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ERAS PTCT Biotechnology median
Debt to equity 0.00 (14.86) 0.00
Current ratio 8.29 3.27 4.97
Net debt to EBITDA 1.93 0.73 1.01

Dividend

Metric ERAS PTCT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ERAS PTCT Biotechnology median
Market cap 4.64b 5.49b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack